Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹4Cr
Rev Gr TTM
Revenue Growth TTM
11,950.00%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

HEMORGANIC
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | | | | | | | | | 11,950.0 | | | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
Operating Profit Operating ProfitCr |
| | | | | -1,050.0 | | | | 5.8 | | | |
Other Income Other IncomeCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Growth YoY PAT Growth YoY% | -400.0 | | | | -360.0 | 100.0 | -900.0 | | 260.9 | | 62.5 | -100.0 |
| | | | | -1,150.0 | | | | 15.3 | | | |
| -0.1 | -0.1 | 0.0 | 0.0 | -0.7 | 0.0 | -0.2 | -0.2 | 1.1 | -0.3 | -0.1 | -0.5 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| -77.7 | -29.9 | 439.3 | -85.5 | -37.1 | 407.5 | -97.1 | -15.4 | -29.7 | 366.7 | 10,678.1 | -0.2 |
| 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
Operating Profit Operating ProfitCr |
| -38.4 | -50.2 | -13.1 | -170.4 | -219.7 | -7.9 | -593.2 | -911.6 | -1,137.5 | -1,099.1 | -1.8 | -2.9 |
Other Income Other IncomeCr | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| -391.5 | -679.4 | 90.4 | -88.2 | 18.9 | 81.8 | -119.3 | -30.3 | 12.5 | -383.7 | 162.1 | -45.1 |
| -66.7 | -741.5 | -13.1 | -170.3 | -219.7 | -7.9 | -593.2 | -913.1 | -1,137.5 | -1,179.0 | 6.8 | 3.7 |
| -0.3 | -2.4 | -0.2 | -0.4 | -0.3 | -0.1 | -0.1 | -0.2 | -0.2 | -0.8 | 0.5 | 0.3 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| -2 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -4 | -4 | -4 | -4 |
Current Liabilities Current LiabilitiesCr | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 4 |
Non Current Liabilities Non Current LiabilitiesCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 5 | 5 |
Non Current Assets Non Current AssetsCr | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
Investing Cash Flow Investing Cash FlowCr | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing Cash Flow Financing Cash FlowCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
|
Free Cash Flow Free Cash FlowCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
| -61.4 | 94.8 | 193.5 | 81.6 | 35.4 | -27.3 | 28.8 | 7.1 | -196.2 | 450.8 | -220.7 |
CFO To EBITDA CFO To EBITDA% | -106.7 | 1,401.3 | 193.5 | 81.6 | 35.4 | -27.3 | 28.8 | 7.1 | -196.2 | 483.6 | 816.5 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 3 | 7 | 6 | 5 | 0 | 4 | 5 | 18 | 2 | 4 | 3 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 19.1 |
Price To Sales Price To Sales | 19.5 | 59.3 | 10.2 | 55.9 | 0.0 | 14.4 | 507.0 | 1,780.0 | | 177.0 | 1.3 |
Price To Book Price To Book | 2.5 | 15.3 | 15.2 | 19.6 | 0.0 | 35.1 | 76.8 | 5,130.0 | -47.3 | -11.2 | -20.4 |
| -50.7 | -115.6 | -76.5 | -34.4 | -0.5 | -183.5 | -106.3 | -286.3 | -43.6 | -18.9 | -103.4 |
Profitability Ratios Profitability Ratios |
| 19.2 | 37.8 | 11.5 | 9.3 | -28.8 | 31.1 | 44.3 | -36.5 | 66.7 | 31.7 | 8.9 |
| -38.4 | -50.2 | -13.1 | -170.4 | -219.7 | -7.9 | -593.2 | -911.6 | -1,137.5 | -1,099.1 | -1.8 |
| -66.7 | -741.5 | -13.1 | -170.3 | -219.7 | -7.9 | -593.2 | -913.1 | -1,137.5 | -1,179.0 | 6.8 |
| -8.2 | -197.3 | -19.5 | -43.7 | -54.9 | -18.9 | -47.5 | -161.8 | 341.3 | -26.7 | 1.9 |
| -8.5 | -197.3 | -19.5 | -57.9 | -88.6 | -19.2 | -72.8 | -1,816.2 | 106.6 | 83.7 | -108.2 |
| -7.7 | -153.2 | -6.9 | -14.8 | -12.6 | -8.8 | -20.5 | -26.1 | -15.9 | -24.8 | 3.3 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
Hemo Organic Limited is an Indian public entity currently undergoing a fundamental strategic pivot. Historically a manufacturer of **Ayurvedic** and **Unani** preparations, the company is transitioning into a diversified **Trading and Distribution** powerhouse. This transformation is characterized by aggressive capital raising, a complete overhaul of the management team, and an expansion of its constitutional mandate to include high-growth sectors such as **Agri-commodities**, **Textiles**, and **Metals**.
---
### **Strategic Pivot: From Niche Manufacturing to Multi-Sector Trading**
The company has formally amended its **Main Object Clause** in the Memorandum of Association to facilitate a move away from its legacy chemical and organic roots. The current operational scope now encompasses:
* **Agri-Commodities:** Focused on the trading and distribution of **Rice** and other food grains.
* **Textiles:** Trading in a wide array of fabrics including **Silk, Synthetic, Woolen, and Cotton**, as well as yarn and readymade garments.
* **Metals (Authorized):** Strategic intent to trade, import, and export **Copper** and copper alloys, including scrap, foils, wires, and sheets.
* **Pharmaceuticals & Life Sciences:** Retaining and expanding its footprint in the manufacturing and retail of medicines, **biologicals**, **nutraceuticals**, and dietary supplements.
---
### **Capital Restructuring and Funding Roadmap**
To support its new business lines and address liquidity needs, Hemo Organic is executing a multi-pronged financial strategy:
* **Preferential Issue (February 2026):** Allotment of **3,400,000 Convertible Warrants** at **Rs. 12.50** per warrant (inclusive of a **Rs. 2.50 premium**). These are convertible into equity within **18 months**, which will effectively double the paid-up equity capital from **Rs. 3.46 Crores** to **Rs. 6.86 Crores**.
* **Rights Issue (March 2025):** The company has filed a Draft Letter of Offer with the **BSE** for a Rights Issue seeking to aggregate up to **Rs. 20.00 Crores**.
* **Expanded Borrowing Mandate:** Shareholders have authorized an increase in borrowing limits up to **Rs. 100 Crores** to facilitate both organic growth and potential inorganic acquisitions.
* **Debt-to-Equity Flexibility:** Provision for up to **Rs. 5.00 Crores** in unsecured loans from directors/promoters, with the option to convert this debt into equity.
* **Authorized Capital Growth:** Reflecting its expansionary scale, the company increased its **Authorised Share Capital** from **Rs. 3.50 Crores** (August 2024) to **Rs. 13.45 Crores** (January 2026).
---
### **Operational Infrastructure and Relocation**
The company has shifted its administrative and operational hub to Ahmedabad to better align with its trading objectives.
| Feature | Details |
| :--- | :--- |
| **Registered Office (New)** | **Uttamnagar, Ahmedabad** (Effective Feb 2026); previously Sumel Business Park 7, Ahmedabad. |
| **Primary Segment** | **Single Segment**: Trading and Distribution. |
| **Accounting Standard** | **Ind AS** (Indian Accounting Standards). |
| **Use of Proceeds** | **75%** for Working Capital and Infrastructure; **25%** for General Corporate Purposes. |
---
### **Leadership and Governance Transition**
A significant management refresh occurred in **May 2024**, aimed at stabilizing the company’s administrative and compliance functions:
* **Mr. Vishwambar Kameshwar Singh (Managing Director):** Appointed May 29, 2024. He oversees administration, HR, and business expansion. Notably, he serves **without financial compensation**, signaling a commitment to the company's turnaround.
* **Mr. Murlidhar Joshi (CFO):** Appointed May 29, 2024, to lead financial recovery.
* **Ms. Garima Dineshkumar Jain (Company Secretary):** Serves as the Compliance Officer.
* **Board Expertise:** The board includes independent directors with specialized backgrounds in **Capital Markets** (Mr. Deepak Ashokkumar Rochani) and **Legal/Secretarial Compliances** (Ms. Hiral Vinodbhai Patel).
---
### **Critical Risk Factors and Audit Qualifications**
Investors should note that Hemo Organic faces substantial financial and regulatory headwinds that challenge its "going concern" status.
#### **1. Financial Instability**
* **Negative Net Worth:** As of **March 31, 2025**, accumulated losses have fully eroded the company’s **paid-up capital and reserves**.
* **Liquidity Deficit:** Current liabilities consistently exceed current assets, leading to persistent net losses.
#### **2. Persistent Audit Qualifications**
Statutory auditors have issued **Qualified Opinions** for several years (FY 2023-24 through Feb 2026) citing:
* **Unconfirmed Balances:** A lack of third-party confirmations for **Trade Receivables** and **Trade Payables**.
* **Banking Discrepancies:** Inability to verify transactions for **4 out of 5 bank accounts** (claimed as dormant by management).
* **Accounting Non-compliance:** Failure to charge **depreciation** on fixed assets and non-adherence to **Ind AS** regarding Deferred Tax Assets/Liabilities.
* **Audit Trail:** The accounting software lacks the mandatory **edit log (audit trail)** facility required by law.
#### **3. Regulatory and Compliance History**
| Compliance Area | Status / Risk Detail |
| :--- | :--- |
| **BSE Listing Status** | Flagged as **'SDD Non-compliant'** (System Driven Disclosures) as of Sept 2025. |
| **KMP Vacancies** | History of significant delays in appointing a **Company Secretary** and **CFO** (e.g., CS post vacant for 20 months). |
| **Fines and Penalties** | Previous penalties imposed by **BSE** for **Regulation 6(1)** violations and late payment of **Annual Listing/Custody Fees**. |
| **Internal Audit** | Non-compliance with **Section 138** of the Companies Act for **FY 2022-23**. |
---
### **Market and Macroeconomic Exposure**
The company’s performance is highly sensitive to external variables:
* **Climatic Dependency:** The **Rice** trading business is vulnerable to **monsoon patterns** and irregular rainfall, which directly impact supply and pricing.
* **Sector Volatility:** Exposure to the **Indian Chemical Industry** (projected at **US$ 304 billion by 2025**) and the cyclical nature of the textile and agrochemical markets.
* **Policy and Geopolitics:** Reliance on government policy for food grain exports and vulnerability to **currency fluctuations** and trade restrictions.
* **Competitive Landscape:** The trading sector has low entry barriers, leading to high competition and potential volatility in the investor base.